Search
Ulcerative Colitis Paid Clinical Trials in New Hampshire
A listing of 6 Ulcerative Colitis clinical trials in New Hampshire actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
The state of New Hampshire currently has 6 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Lebanon, Manchester, Nashua and Portsmouth.
Featured Trial
Ulcerative colitis (UC) Trials
Recruiting
Ulcerative colitis (UC) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Ulcerative colitis (UC)
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Ulcerative Colitis Study For Adolescents
Recruiting
We are looking for children 2 to 17 years old diagnosed with ulcerative colitis to join our latest study to help us further develop our knowledge of UC and discover potential new medication options for those whose previous treatment has not been successful.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Ulcerative Colitis Chronic Moderate
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Featured Trial
Ulcerative Colitis Clinical Trial
Recruiting
Are you or someone you know struggling with Ulcerative Colitis? A clinical study in the area is currently open to enroll participants. Eligible adults will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Ulcerative Colitis Chronic Mild
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
05/31/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Ulcerative Colitis
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Recruiting
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment), or until marketing authorization is obtained in the participant's country, whiche... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/01/2024
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Ulcerative Colitis
ABTECT - Maintenance
Recruiting
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/23/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Ulcerative Colitis
Hyperbaric Oxygen Therapy for Ulcerative Colitis
Recruiting
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small mole... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/12/2024
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Ulcerative Colitis
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Dartmouth Hitchcock, Lebanon, New Hampshire
Conditions: Ulcerative Colitis, Crohn Disease
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
1 - 6 of 6